BBZA GER Week ended 31 Jul 2026

Weekly Investor Report

Name: BBZA weekly investor report
Creator: Sharemaestro
License: https://sharemaestro.com/data-license/

BB Biotech AG · Healthcare · Biotechnology

Open interactive chart View report data

Latest close 55.30 EUR

65.6% latest week

Weekly setup

Constructive, but selective

The weekly trend is active. Price is 66.0% above the Trend Line and sits at 92.0% of its 52-week range. The latest completed week returned 65.6%, after a 65.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is inexpensive relative to peers. The latest news-sentiment score is 56/100. Near-term considerations: price is close to its 52-week high.

Setup score 71 out of 100

Latest Close 55.30 EUR 31 Jul 2026

1W Return 65.6% latest completed week

4W Return 65.6% short-term follow-through

12W Return 65.6% quarterly tape

Trend Breadth 73.1% 38 of 52 weeks active

Volume Ratio 13.0x vs 13-week average

What is working

The trend backdrop is active with a 19-week active streak.
Price is above the Trend Line, keeping the weekly tape constructive.
Price is above Fair Value, showing premium demand versus the model.
Activity pressure is positive on the latest completed week.

What could go wrong

Next-week expectancy is negative at 12.59% based on similar historical setup states.
1 reversal markers appear in the recent smart-money tape.
Recent volatility is running well above the one-year baseline.

What to watch next

Price is close to its 52-week high; watch for continuation or exhaustion.
Trend Line remains the key weekly regime level.
Activity pressure is the gauge to monitor for confirmation or fade.
A volume ratio above 1.5x would show stronger participation in the next move.

Price follow-through 65.6% Latest completed week; four-week move 65.6%. Indicator stack 85/58 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 12.59% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 56/100 9 relevant articles in the latest sentiment read.

01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 66.0% above the Trend Line and sits at 92.0% of its 52-week range. The latest completed week returned 65.6%, after a 65.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value

Price Trend Line Fair Value

Position in the 52-week range

Close Trend Fair

31.15 EUR 92.0% 57.40 EUR

Range location92.0%Shows where the latest close sits between the 52-week low and high.

Trend distance66.0%Price premium or discount versus the weekly Trend Line.

Fair-value gap60.7%Premium demand or model discount versus Sharemaestro Fair Value.

High-water gap-3.7%Distance from the latest 52-week high.

02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 13.0x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction

6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul

Up week Down week

Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.6412-week average 0.68

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.

Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.

Positive leadership11/12Weeks with positive relative leadership in the latest 12-week window.

Activity pressure0.64Current proprietary activity-pressure read.

Buy signals0Accumulation signal count in the latest 12 weeks.

Reversal markers11 reversal markers

No recent accumulation markers. 1 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 65.6% over four weeks, 65.6% over 12 weeks, and 77.5% over one year. The current trend has remained active for 19 consecutive weeks.

Performance by holding period

1W65.6%

4W65.6%

12W65.6%

26W77.5%

52W77.5%

Active trend streak19 weeks

Active weeks in one year38

Trend breadth73.1%

Activity pressure vs relative leadership

Activity pressureRelative leadership

Pressure0.22Latest activity-pressure read.

Pressure change47.3%Four-week change in activity pressure.

Leadership61.86Latest relative-leadership reading.

RS change4489.6%Four-week change in relative leadership.

04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is inexpensive relative to peers.

Open full factor analysis

Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 67% Model confidence 67%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength90/100Blend of value, momentum, and quality. Underlying universe rank 11; rank 1 is best.

Value81/100Relative valuation strength. Underlying universe rank 20; rank 1 is best.

Quality65/100Profitability and accounting quality. Underlying universe rank 36; rank 1 is best.

Momentum60/100Medium-term price momentum. Underlying universe rank 41; rank 1 is best.

Growth100/100Revenue and earnings growth. Underlying universe rank 1; rank 1 is best.

How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E: 2.3x
Price / sales: 2.2x
EV / EBITDA: -
Free-cash-flow yield: 10.9%

Business quality

Margins and the return generated on invested capital.

Gross margin: -
Operating margin: -
Free-cash-flow margin: 21.7%
Return on invested capital: -

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth: 613.1%
EPS growth: 656.4%
Free-cash-flow growth: 1.5%
Piotroski F-score: 3/9

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield: 7.2%
Buyback yield: -0.8%
Shareholder yield: 6.4%
Net debt / EBITDA: -

05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment56/100

Weighted news tone is neutral across 9 relevant articles.

2 positive · 7 neutral · 0 negative

Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal

06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.

Options expected move-Nearest-chain priced movement where available.

52-week drawdown-3.7%Distance below the 52-week high.

13-week volatility17.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

6 Feb 6 Mar 3 Apr 1 May 29 May 26 Jun 31 Jul

Weeks higher2 of 260 weeks finished lower.

Best week+65.6%Week of 31 Jul.

Worst week+0.0%Week of 6 Feb.

Latest week+65.6%Week of 31 Jul.

Shape of recent returns

Strong gains2

Modest gains0

Flat weeks24

Modest losses0

Sharp losses0

Recent vol17.5%13-week weekly-return volatility.

Base vol9.0%52-week weekly-return volatility.

Up/down split2/0Count of positive and negative weeks in the 52-week window.

Average skew36.4% / -Average positive week versus average negative week.

07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

SectorDE Healthcare

4-week rank1 / 78

Group average-0.2%

Trend breadth38.5%

Trend38.5%active weekly trend signals

MD67.9%positive activity pressure

RS37.2%positive relative leadership

Four-week leaders

BBZA · GER65.6%B72 · GER38.9%DRW3 · GER27.4%DRW8 · GER15.6%BOX · GER13.3%

IndustryDE Biotechnology

4-week rank1 / 11

Group average5.0%

Trend breadth27.3%

Trend27.3%active weekly trend signals

MD54.5%positive activity pressure

RS27.3%positive relative leadership

Four-week leaders

BBZA · GER65.6%B72 · GER38.9%RGO · GER12.1%FYB · GER0.3%GE9 · GER-0.3%

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape68/100

Trend, activity pressure, participation, and risk combine to a 68/100 tape read.

Indicator analysis78/100

Latest 12-week confirmation: trend 12/12, activity pressure 10/12, relative leadership 11/12.

Activity pressure 0.64; 1 reversal markers Next-Week ExpectancyNegative 12.59%

Next-week expectancy is negative with a 12.59% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors74/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 93; Small Cap Core rank 22 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment56/100

Weighted news tone is neutral across 9 relevant articles.

BB Biotech posts strong interim profit and shifts to yield-based dividend policy Insiders50/100

No recent insider transaction evidence is stored.

Earnings50/100

No stored earnings event is currently attached to this ticker.

Week	Close	Return	Trend Line	Fair Value	Pressure	Leadership	Volume	Trend
31 Jul 2026	55.30 EUR	65.6%	33.31 EUR	34.41 EUR	0.22	61.86	14.1K	On
24 Jul 2026	33.40 EUR	0.0%	32.50 EUR	34.29 EUR	-0.10	1.03	0	On
17 Jul 2026	33.40 EUR	0.0%	32.43 EUR	34.34 EUR	-0.05	2.19	0	On
10 Jul 2026	33.40 EUR	0.0%	32.35 EUR	34.37 EUR	0.03	1.32	0	On
3 Jul 2026	33.40 EUR	0.0%	32.28 EUR	34.40 EUR	0.15	-1.41	0	On
26 Jun 2026	33.40 EUR	0.0%	32.20 EUR	34.41 EUR	0.28	3.05	0	On
19 Jun 2026	33.40 EUR	0.0%	32.13 EUR	34.41 EUR	0.42	1.89	0	On
12 Jun 2026	33.40 EUR	0.0%	32.05 EUR	34.43 EUR	0.54	3.46	0	On
5 Jun 2026	33.40 EUR	0.0%	31.98 EUR	34.45 EUR	0.64	3.06	0	On
29 May 2026	33.40 EUR	0.0%	31.90 EUR	34.48 EUR	0.72	1.77	0	On
22 May 2026	33.40 EUR	0.0%	31.83 EUR	34.50 EUR	0.80	2.81	0	On
15 May 2026	33.40 EUR	0.0%	31.75 EUR	34.52 EUR	0.86	7.04	0	On
8 May 2026	33.40 EUR	0.0%	31.68 EUR	34.55 EUR	0.90	5.60	0	On
1 May 2026	33.40 EUR	0.0%	31.60 EUR	34.59 EUR	0.92	6.02	0	On

How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.